NZ330482A - Compositions comprising formoterol and budesonide for treating respiratory disorders - Google Patents

Compositions comprising formoterol and budesonide for treating respiratory disorders

Info

Publication number
NZ330482A
NZ330482A NZ330482A NZ33048297A NZ330482A NZ 330482 A NZ330482 A NZ 330482A NZ 330482 A NZ330482 A NZ 330482A NZ 33048297 A NZ33048297 A NZ 33048297A NZ 330482 A NZ330482 A NZ 330482A
Authority
NZ
New Zealand
Prior art keywords
formoterol
budesonide
respiratory disorders
solvate
treating respiratory
Prior art date
Application number
NZ330482A
Inventor
Jan Trofast
Anders Ullman
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of NZ330482A publication Critical patent/NZ330482A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Abstract

The present invention relates to a composition comprising: a) formoterol, a pharmaceutically acceptable salt or solvate, or solvate of the salt and b) budesonide the molar ration of a):b) being 1:30 to 1:36 Also claimed is a kit comprising: a) a vessel containing formoterol a pharmaceutically acceptable salt or solvate, or solvate of the salt b) second vessel containing budesonide c) instructions for adminstering the components. Finally claimed is the use of the above composition for treating respiratory disorders like asthma.
NZ330482A 1996-10-08 1997-09-24 Compositions comprising formoterol and budesonide for treating respiratory disorders NZ330482A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9603669A SE9603669D0 (en) 1996-10-08 1996-10-08 New combination

Publications (1)

Publication Number Publication Date
NZ330482A true NZ330482A (en) 1999-11-29

Family

ID=20404167

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ330482A NZ330482A (en) 1996-10-08 1997-09-24 Compositions comprising formoterol and budesonide for treating respiratory disorders

Country Status (18)

Country Link
EP (1) EP0871450A1 (en)
JP (1) JP2000502365A (en)
KR (1) KR19990071975A (en)
AR (1) AR013614A1 (en)
AU (1) AU715319B2 (en)
BR (1) BR9706822A (en)
CA (1) CA2239308A1 (en)
CZ (1) CZ176198A3 (en)
HU (1) HUP9901674A3 (en)
MY (1) MY128337A (en)
NO (1) NO982414L (en)
NZ (1) NZ330482A (en)
PL (1) PL327037A1 (en)
SE (1) SE9603669D0 (en)
SK (1) SK75198A3 (en)
TW (1) TW470647B (en)
WO (1) WO1998015280A1 (en)
ZA (1) ZA978889B (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
US5980949A (en) * 1994-10-03 1999-11-09 Astra Aktiebolag Formulation for inhalation
SE9700136D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700134D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700135D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700133D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation
AU8135098A (en) * 1997-06-27 1999-01-19 Astra Aktiebolag New combination of antiasthma medicaments
SE9703407D0 (en) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (en) * 1998-06-11 1998-06-11 Astra Ab New use
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
SE9900834D0 (en) * 1999-03-09 1999-03-09 Astra Ab Novel combination
DE19921693A1 (en) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
FI20002216A0 (en) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Combination particles for asthma therapy
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
SE0200312D0 (en) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
SE527069C2 (en) 2003-06-19 2005-12-13 Mederio Ag Method and apparatus for administering drug powder
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
IN2014MN00380A (en) 2006-06-30 2015-06-19 Iceutica Pty Ltd
EP2327403A3 (en) 2007-02-19 2011-08-31 Cipla Limited Pharmaceutical combinations of at least two bronchodilators
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
CA2763941A1 (en) 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
JP6285866B2 (en) 2011-11-23 2018-02-28 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． Natural complex hormone replacement preparations and therapies
RU2697862C2 (en) * 2012-02-28 2019-08-21 Айсьютика Холдингз Инк. Inhalation pharmaceutical compositions
ITMI20130571A1 (en) 2013-04-10 2014-10-11 Zambon Spa PHARMACEUTICAL COMPOSITION CONTAINING BUDESONIDE AND FORMOTEROL

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0613371T3 (en) * 1991-12-18 2002-05-13 Astrazeneca Ab New combination of formoterol and budesonide

Also Published As

Publication number Publication date
SK75198A3 (en) 1998-11-04
AU4578297A (en) 1998-05-05
JP2000502365A (en) 2000-02-29
NO982414D0 (en) 1998-05-27
PL327037A1 (en) 1998-11-09
MY128337A (en) 2007-01-31
AR013614A1 (en) 2001-01-10
SE9603669D0 (en) 1996-10-08
WO1998015280A1 (en) 1998-04-16
TW470647B (en) 2002-01-01
HUP9901674A2 (en) 1999-09-28
HUP9901674A3 (en) 2001-04-28
KR19990071975A (en) 1999-09-27
BR9706822A (en) 1999-03-23
AU715319B2 (en) 2000-01-20
ZA978889B (en) 1998-04-08
CZ176198A3 (en) 1998-09-16
EP0871450A1 (en) 1998-10-21
NO982414L (en) 1998-05-27
CA2239308A1 (en) 1998-04-16

Similar Documents

Publication Publication Date Title
NZ330482A (en) Compositions comprising formoterol and budesonide for treating respiratory disorders
ES2133130A1 (en) Novel formulation
OA09868A (en) Non-chorofluorocarbon aerosol formulation.
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
CA2123909A1 (en) New combination of formoterol and budesonide
CA2259621A1 (en) Isocoumarin derivatives and their use in medicines
CA2334411A1 (en) Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
CA2098302A1 (en) Medicaments
SI1007017T2 (en) Budesonide/formoterol formulation for inhalation having a poured bulk density of 0.30 to 0.36 g/ml, a process for preparing the formulation and the use thereof
IL122733A0 (en) Pharmaceutical compositions for use in the treatment of allergic asthma
WO1998009599A3 (en) The new use of dicaffeoylquinic acid for treating hepatitis b and the diseases related with retrovirus, and the new caffeoylquinic acid derivatives
CA2129235A1 (en) Inhibition of respiratory burst using posttranslational modification inhibitors
HUP0002533A2 (en) New combination of antiasthma medicaments
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
GR1002576B (en) Pharmaceutical compositions and a process for the preparation thereof.
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
EP1101493A3 (en) New combination of formoterol and budesonide
UA29461C2 (en) An agent for treatment of amyloidosis, a method for treatment of amyloidosis
IL95892A0 (en) Aroyl-ureas,their preparation and pharmaceutical compositions containing them
IE840198L (en) Therapeutic use of nafazatrom
Tyeb et al. Comparison of droperidol and metoclopramide as antimetics.
LV5179A3 (en) Preparation of "ethoxidine" for prophylaxis and treatment of almost all diseases of the lungs and bowels
ZA965578B (en) Compositions for the treatment and diagnosis of body weight disorders including obsesity

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)